Alpha Cognition【ACOG】銘柄情報

Alpha Cognition Inc (ACOG) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

7.89

( 1.28% )

買値

6.93

売値

8.75

出来高

51,979

7.35 日の範囲 8.10

4.50 52 週間の範囲 11.54

時価総額

171.798M

前日終値

7.79

始値

7.84

時刻

7.89

最終取引時間

財務取引量

US$ 401,569

VWAP

7.7256

平均取引量 (3 か月)

US$ 44,053

発行済株式数

21,774,104

配当利回り

PER

-5.7

1 株当たり利益 (EPS)

-1.37

歳入

10.83M

純利益

-25.42M

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. ... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.alphacognition.com

本社

Grapevine, United States

設立

2026

Alpha Cognition Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ACOG. The last closing price for Alpha Cognition was US$7.79. Over the last year, Alpha Cognition shares have traded in a share price range of US$ 4.50 to US$ 11.54.

Alpha Cognition currently has 21,774,104 shares in issue. The market capitalisation of Alpha Cognition is US$171.80 million. Alpha Cognition has a price to earnings ratio (PE ratio) of -5.70.

Form 8-K - Current report

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K/A - Current report: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company...

Form 8-K - Current report

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.3	19.7268588771	6.59	8.04	6.25	67369	6.73844398	CS
4	1.83	30.198019802	6.06	8.04	5.55	44147	6.43186288	CS
12	1.24	18.6466165414	6.65	8.04	5.33	41124	6.32168455	CS
26	1.32	20.0913242009	6.57	8.04	4.5	56722	5.92128139	CS
52	-1.51	-16.0638297872	9.4	11.54	4.5	71258	6.76208427	CS
156	0.89	12.7142857143	7	11.54	3.75	83025	6.77266473	CS
260	0.89	12.7142857143	7	11.54	3.75	83025	6.77266473	CS